| [1] |
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC[J]. Eur Heart J,2021,42(5):373-498.
|
| [2] |
Chan NY, Orchard J, Agbayani MJ, et al. 2021 Asia Pacific Heart Rhythm Society (APHRS) practice guidance on atrial fibrillation screening[J]. J Arrhythm,2022,38(1):31-49.
|
| [3] |
中华医学会心血管病学分会, 中国生物医学工程学会心律分会. 心房颤动诊断和治疗中国指南[J]. 中华心血管病杂志,2023,51(6):572-618.
|
| [4] |
Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)[J]. Eur Heart J, 2024,45(36):3314-3414.
|
| [5] |
Abdel-Qadir H, Gunn M, Lega IC, et al. Association of diabetes duration and glycemic control with stroke rate in patients with atrial fibrillation and diabetes: a population-based cohort study[J]. J Am Heart Assoc,2022,11(4):e023643. doi: 10.1161/JAHA.121.023643.
|
| [6] |
Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure[J]. N Engl J Med,2021,384(2):117-128.
|
| [7] |
Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction[J]. N Engl J Med,2021,385(16):1451-1461.
|
| [8] |
Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction[J]. N Engl J Med,2022,387(12):1089-1098.
|
| [9] |
Hirota T, Kubo T, Baba Y, et al. Clinical profile of thromboembolic events in patients with hypertrophic cardiomyopathy in a regional Japanese cohort- results from Kochi RYOMA study[J]. Circ J,2019,83(8):1747-1754.
|
| [10] |
Vilches S, Fontana M, Gonzalez-Lopez E, et al. Systemic embolism in amyloid transthyretin cardiomyopathy[J]. Eur J Heart Fail,2022,24(8):1387-1396.
|
| [11] |
Hijazi Z, Lindbäck J, Alexander JH, et al. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation[J]. Eur Heart J,2016,37(20):1582-1590.
|
| [12] |
Mori N, Sotomi Y, Hirata A, et al. External validation of the ORBIT bleeding score and the HAS-BLED score in nonvalvular atrial fibrillation patients using direct oral anticoagulants (Asian data from the DIRECT registry)[J]. Am J Cardiol,2019,124(7):1044-1048.
|
| [13] |
Whitlock RP, Belley-Cote EP, Paparella D, et al. Left atrial appendage occlusion during cardiac surgery to prevent stroke[J]. N Engl J Med,2021,384(22):2081-2091.
|
| [14] |
Wazni OM, Dandamudi G, Sood N, et al. Cryoballoon ablation as initial therapy for atrial fibrillation[J]. N Engl J Med,2021,384(4):316-324.
|
| [15] |
Kuniss M, Pavlovic N, Velagic V, et al. Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation[J]. Europace,2021,23(7):1033-1041.
|
| [16] |
Gonzalez-Pacheco H, Marquez MF, Arias-Mendoza A, et al. Clinical features and in-hospital mortality associated with different types of atrial fibrillation in patients with acute coronary syndrome with and without ST elevation[J]. J Cardiol, 2015,66(2):148-154.
|
| [17] |
Krijthe BP, Leening MJ, Heeringa J, et al. Unrecognized myocardial infarction and risk of atrial fibrillation: the Rotterdam Study[J]. Int J Cardiol, 2013,168(2):1453-1457.
|
